Bromelains

Summary

Bromelains (CHEMBL2109027) is an approved unknown (ATC M09AB03); indicated across 4 conditions including pulpitis and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: M09AB03 (+1 more)
• Indications: 4 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109027
Name	Bromelains
Type	Unknown
Max phase	4
ATC	M09AB03, D03BA03

Also known as: Ananase, Bromelain, Bromelaina, Bromelaines, Bromelains, Bromelin, Debridase, E-1101(iii), Edemase d, Extranase, Ins no.1101(iii), Ins-1101(iii)

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pulpitis	2	MONDO:0006937	EFO:1001139
neoplasm	2	MONDO:0005070	MONDO:0004992
pseudomyxoma peritonei	1	MONDO:0017048	EFO:0007456

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE2	4
Not specified	4
PHASE4	3
PHASE3	1
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01356693	PHASE4	UNKNOWN	Bromelin, a Compound Prepared With Ananas Comocus Extract and Honey, for Acute Cough
NCT04468139	PHASE4	UNKNOWN	The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19
NCT04669119	PHASE4	UNKNOWN	Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.
NCT06786403	PHASE3	NOT_YET_RECRUITING	The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcers
NCT06981767	PHASE2	RECRUITING	Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Oral Lichen Planus
NCT02340845	PHASE2	UNKNOWN	Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans
NCT03976973	PHASE2	UNKNOWN	BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
NCT04512482	PHASE2	COMPLETED	Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse
NCT05258682	PHASE1/PHASE2	UNKNOWN	Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
NCT04982146	PHASE1	UNKNOWN	Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
NCT05687760	EARLY_PHASE1	UNKNOWN	Effect of Bromelain Versus Calcium Hydroxide as an Intracanal Medication on the Intensity of Postoperative Pain and Bacterial Load Reduction in Necrotic Single Rooted Lower Premolars
NCT07115212	Not specified	RECRUITING	Bromelain for Post-surgery Facial Swelling
NCT01524159	Not specified	COMPLETED	Bromelain and Cardiovascular Risk Factors in Diabetes
NCT03586232	Not specified	WITHDRAWN	Arnica Montana and Bromelain in Rhinoplasty
NCT04657874	Not specified	COMPLETED	Bromelain and Escin in the Reduction of Postoperative Sequelae in Periodontal and Implant Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).